Search-led Peptide Reference
Epitalon vs Epithalon: spelling, evidence and 2026 regulatory status
Source-based guide to epitalon vs epithalon FDA status 2026 evidence, with molecular identity, evidence limits, analytical checks and dated regulatory verification.
Direct answer
A name-normalization page must separate transliteration variants from proof of chemical identity and must date-stamp any regulatory statement.
Search engines and AI summaries often collapse aliases, molecule classes, preclinical observations and regulatory events into one confident sentence. A reliable archive record keeps those fields separate and links each claim to a date-stamped primary source.
Name and molecular identity
Epitalon, Epithalon and the tetrapeptide sequence Ala-Glu-Asp-Gly are frequently used in overlapping records.
Verify the four-residue sequence, terminal state, salt/counterion, intact mass, chromatographic purity and net peptide content.
| Identity field | What to verify |
|---|---|
| Name and aliases | Exact spelling, development code and whether an alias is molecule-specific |
| Structure | Sequence or chemical structure, termini, modification and conjugation |
| Molecular form | Free form, salt/counterion, hydration state and calculated mass basis |
| Analytical support | Orthogonal identity, purity, content and lot-linked raw-data references |
How to compare without overclaiming
Do not merge Epitalon with pineal peptide mixtures, thymic preparations or products that omit a complete sequence and molecular form.
Cross-study comparisons require matched populations, models, exposure, duration, endpoints and analysis methods. A receptor label, publication count or high HPLC area percentage cannot by itself establish clinical equivalence, safety, effectiveness or sample identity.
Evidence and status review
Organize sources into biochemical or cell studies, animal aging models, small human reports, reviews and regulator proceedings. A committee recommendation is not the same as marketing approval or an effectiveness finding.
- Start with the exact name and development code in PubMed and a trial registry.
- Separate biochemical, cellular, animal and human evidence.
- Record the jurisdiction and document date for every regulatory claim.
- Open the primary paper or regulator document instead of citing a search snippet.
- Mark missing sequence, method or lot information as unknown rather than inferred.
COA and procurement-document checklist
- Product name, sequence or structure and declared molecular form agree across label, specification and COA.
- Batch number, test date, method identifier and approval/version fields are present.
- Identity, chromatographic purity and net content are reported as different measurements.
- Chromatogram and mass data correspond to the same lot and are reviewable.
- Water, counterion, residual solvent, elemental or endotoxin tests are included when scientifically relevant.
Primary-source verification routes
Statuses and database records change. Save the document date, jurisdiction, registry identifier and access date; use the primary document for consequential claims.